{"protocolSection": {"identificationModule": {"nctId": "NCT00885352", "orgStudyIdInfo": {"id": "0431-128"}, "secondaryIdInfos": [{"id": "2009_577"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)", "officialTitle": "A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Metformin and Pioglitazone"}, "statusModule": {"statusVerifiedDate": "2017-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-04-15", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2010-11-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-11-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-04-20", "studyFirstSubmitQcDate": "2009-04-20", "studyFirstPostDateStruct": {"date": "2009-04-21", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-11-04", "resultsFirstSubmitQcDate": "2011-12-27", "resultsFirstPostDateStruct": {"date": "2012-02-01", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-04-27", "lastUpdatePostDateStruct": {"date": "2017-05-23", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will examine the safety and efficacy of the addition of sitagliptin (MK-0431) compared to placebo in patients with type 2 diabetes mellitus with inadequate glycemic control who are taking pioglitazone and metformin."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 313, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sitagliptin", "type": "EXPERIMENTAL", "description": "Sitagliptin 100 mg tablet orally once daily for 26 weeks.", "interventionNames": ["Drug: Sitagliptin", "Drug: Pioglitazone", "Drug: Metformin", "Drug: Glipizide"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo to sitagliptin orally once daily for 26 weeks.", "interventionNames": ["Drug: Comparator: Placebo", "Drug: Pioglitazone", "Drug: Metformin", "Drug: Glipizide"]}], "interventions": [{"type": "DRUG", "name": "Sitagliptin", "description": "Sitagliptin 100 mg tablet orally once daily for 26 weeks.", "armGroupLabels": ["Sitagliptin"], "otherNames": ["Januvia", "MK-0431"]}, {"type": "DRUG", "name": "Comparator: Placebo", "description": "Placebo to sitagliptin 100 mg tablet orally once daily for 26 weeks.", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Pioglitazone", "description": "Participants taking 30 mg or more pioglitazone oral tablet(s) daily at screening in combination with metformin will enter a 4-week dose-stable period followed by a 2-week single-blind run-in and a 26-week treatment period. Participants taking 4 mg or more rosiglitazone oral tablet(s) daily at screening in combination with metformin were to be switched to a corresponding dose of pioglitazone prior to starting a 4-week dose-stable period. Participants who are taking less than 30 mg/day or no pioglitazone at screening will be titrated to a stable dose of at least 30 mg pioglitazone once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with pioglitazone will be up to 42 weeks.", "armGroupLabels": ["Placebo", "Sitagliptin"], "otherNames": ["Actos"]}, {"type": "DRUG", "name": "Metformin", "description": "Participants taking 1500 mg or more metformin oral tablet(s) and at least 30 mg pioglitazone or 4 mg rosiglitazone daily at screening will enter a 4-week dose-stable period followed by a 2-week single-blind placebo run-in, and a 26-week treatment period. Participants who are taking less than 1500 mg/day metformin at screening will be titrated to a stable dose of at least 1500 mg metformin once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with metformin will be up to 42 weeks.", "armGroupLabels": ["Placebo", "Sitagliptin"], "otherNames": ["Glucophage"]}, {"type": "DRUG", "name": "Glipizide", "description": "Participants not meeting specific glycemic controls during the 26-week treatment period will use glipizide oral tablets as rescue therapy. In countries where glipizide is not available, participants will receive a sulfonylurea marketed in that country.", "armGroupLabels": ["Placebo", "Sitagliptin"], "otherNames": ["Glucotrol"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Hemoglobin A1c (A1C) at Week 26", "description": "Change from baseline reflects the Week 26 value minus the baseline value. A1C represents the percentage of glycosylated hemoglobin.", "timeFrame": "Baseline and Week 26"}], "secondaryOutcomes": [{"measure": "Change From Baseline in 2-Hour Post-Meal Glucose (PMG) at Week 26", "description": "Change from baseline reflects the Week 26 value minus the baseline value.", "timeFrame": "Baseline and Week 26"}, {"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26", "description": "Change from baseline reflects the Week 26 value minus the baseline value.", "timeFrame": "Baseline and Week 26"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* has type 2 diabetes and is at least 18 years of age and no older than 78 years of age\n* is male or is a female who is unlikely to conceive children\n* is on stable doses of a peroxisome proliferator-activated receptor gamma agonist and metformin OR metformin and a sulfonylurea agent\n\nExclusion Criteria:\n\n* has type 1 diabetes\n* has taken a dipeptidyl peptidase (DPP-4) inhibitor or a glucagon-like peptide-1 (GLP-1) analogue\n* is on a weight loss program that is not in the maintenance phase or has started a weight loss medication within 8 weeks of screening\n* has had surgery within 30 days of screening or has major surgery planned during the study\n* is on or is likely to require treatment with corticosteroids for more than 2 weeks\n* has a history of active liver disease, including hepatitis B or C, cirrhosis, or gallbladder disease\n* is human immunodeficiency virus (HIV) positive\n* has congestive heart failure, or has had new or worsening symptoms of coronary heart disease within 3 months prior to screening\n* has had acute coronary syndrome, coronary artery intervention, or stroke within 3 months of screening\n* has severe active peripheral vascular disease\n* has a history of cancer or blood disorder\n* is pregnant or breast feeding", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "78 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "23116881", "type": "DERIVED", "citation": "Fonseca V, Staels B, Morgan JD 2nd, Shentu Y, Golm GT, Johnson-Levonas AO, Kaufman KD, Goldstein BJ, Steinberg H. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. J Diabetes Complications. 2013 Mar-Apr;27(2):177-83. doi: 10.1016/j.jdiacomp.2012.09.007. Epub 2012 Oct 30."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf\n\nhttp://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Lab abnormalities (the reason for discontinuation cited below) included creatinine, creatinine clearance, and estimated glomerular filtration rate.", "groups": [{"id": "FG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily"}, {"id": "FG001", "title": "Placebo", "description": "Placebo to sitagliptin once daily"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "157"}, {"groupId": "FG001", "numSubjects": "156"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "149"}, {"groupId": "FG001", "numSubjects": "136"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "20"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Contradiction to study medication", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Excluded medication", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Lab abnormalities", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily"}, {"id": "BG001", "title": "Placebo", "description": "Placebo to sitagliptin once daily"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "157"}, {"groupId": "BG001", "value": "156"}, {"groupId": "BG002", "value": "313"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.7", "spread": "8.7"}, {"groupId": "BG001", "value": "56.4", "spread": "9.4"}, {"groupId": "BG002", "value": "56.1", "spread": "9.0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "60"}, {"groupId": "BG001", "value": "58"}, {"groupId": "BG002", "value": "118"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "97"}, {"groupId": "BG001", "value": "98"}, {"groupId": "BG002", "value": "195"}]}]}]}, {"title": "Hemoglobin A1c (A1C)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent of gylcosylated hemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.8", "spread": "1.0"}, {"groupId": "BG001", "value": "8.7", "spread": "1.0"}, {"groupId": "BG002", "value": "8.7", "spread": "1.0"}]}]}]}, {"title": "2-hour post-meal glucose (PMG)", "description": "Participant population included 147 sitagliptin participants and 147 placebo participants.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "275.5", "spread": "66.4"}, {"groupId": "BG001", "value": "266.0", "spread": "62.4"}, {"groupId": "BG002", "value": "270.8", "spread": "64.5"}]}]}]}, {"title": "Fasting plasma glucose (FPG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "179.3", "spread": "44.3"}, {"groupId": "BG001", "value": "173.6", "spread": "38.9"}, {"groupId": "BG002", "value": "176.5", "spread": "41.7"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Hemoglobin A1c (A1C) at Week 26", "description": "Change from baseline reflects the Week 26 value minus the baseline value. A1C represents the percentage of glycosylated hemoglobin.", "populationDescription": "Full analysis set excluded participants without baseline or post-baseline data. Full analysis set with last observation carried forward.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent of glycosylated hemoglobin", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to sitagliptin once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "152"}, {"groupId": "OG001", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.15", "spread": "0.93", "lowerLimit": "-1.29", "upperLimit": "-1.01"}, {"groupId": "OG001", "value": "-0.40", "spread": "1.00", "lowerLimit": "-0.55", "upperLimit": "-0.26"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-Hour Post-Meal Glucose (PMG) at Week 26", "description": "Change from baseline reflects the Week 26 value minus the baseline value.", "populationDescription": "Full analysis set excluded participants without baseline or post-baseline data. Full analysis set with last observation carried forward.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to sitagliptin once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "135"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-54.4", "spread": "64.4", "lowerLimit": "-63.3", "upperLimit": "-45.4"}, {"groupId": "OG001", "value": "-14.7", "spread": "59.6", "lowerLimit": "-23.8", "upperLimit": "-5.6"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26", "description": "Change from baseline reflects the Week 26 value minus the baseline value.", "populationDescription": "Full analysis set excluded participants without baseline or post-baseline data. Full analysis set with last observation carried forward.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "Sitagliptin 100 mg once daily"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to sitagliptin once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "155"}, {"groupId": "OG001", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-20.3", "spread": "49.5", "lowerLimit": "-27.0", "upperLimit": "-13.6"}, {"groupId": "OG001", "value": "-2.8", "spread": "41.6", "lowerLimit": "-9.5", "upperLimit": "3.9"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Weeks 0 to 26", "description": "Participants received glycemic rescue medication if they met specific glycemic goals. Serious adverse events include events that occurred either before or after receiving rescue medication. Other adverse events only include those AEs that occurred prior to a participant receiving rescue medication.", "eventGroups": [{"id": "EG000", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg once daily", "seriousNumAffected": 3, "seriousNumAtRisk": 157, "otherNumAffected": 22, "otherNumAtRisk": 157}, {"id": "EG001", "title": "Placebo", "description": "Placebo to sitagliptin once daily", "seriousNumAffected": 6, "seriousNumAtRisk": 156, "otherNumAffected": 20, "otherNumAtRisk": 156}], "seriousEvents": [{"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}]}, {"term": "Gastric ulcer haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}]}, {"term": "Peritonitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.1", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 157}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}]}, {"term": "Dengue fever", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}]}, {"term": "Cartilage injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}]}, {"term": "Patella fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 157}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}]}, {"term": "Renal colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 13.1", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 157}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}]}], "otherEvents": [{"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 13, "numAtRisk": 157}, {"groupId": "EG001", "numEvents": 15, "numAffected": 14, "numAtRisk": 156}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.1", "stats": [{"groupId": "EG000", "numEvents": 23, "numAffected": 10, "numAtRisk": 157}, {"groupId": "EG001", "numEvents": 16, "numAffected": 7, "numAtRisk": 156}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Canada", "Costa Rica", "Croatia", "Hong Kong", "Italy", "New Zealand", "Peru", "Serbia", "South Africa", "Spain", "Thailand", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000077205", "term": "Pioglitazone"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}, {"id": "D000005913", "term": "Glipizide"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M1693", "name": "Pioglitazone", "asFound": "Registry", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M9023", "name": "Glipizide", "asFound": "Xylocaine", "relevance": "HIGH"}, {"id": "M1677", "name": "Rosiglitazone", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}